Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Inclusion Criteria:

• Eligible patients of either sex, 15 years of age or older
• Patients who are admitted to the department of hematology and oncology
• Provide written informed consent

Exclusion Criteria:

• Patients who have hypersensitivity to β-lactam antibiotics
• Female who are pregnant or breast-feeding
• Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days